Monday 29 June 2009
Allergy Therapeutics plc
("Allergy Therapeutics" or "the Company")
Result of Offer to Qualifying Participants
Allergy Therapeutics plc (AIM: AGY), the specialist pharmaceutical company focused on allergy vaccination, announced a fundraising that included an offer to qualifying shareholders and qualifying employees ("Qualifying Participants") of up to 17,835,233 new ordinary shares of 0.1p each of the Company at a price of 12p per share (the "Offer") on 12 June 2009.
The Company is pleased to announce that, at the close of the Offer, Qualifying Participants had applied for 12,915,375 new ordinary shares of 0.1p each at a price of 12p per share raising approximately £1.5 million.
The Offer was in addition to the placing and subscription, also announced on 12 June 2009, which conditionally raised £20.2 million ("Placing and Subscription").
The Offer, together with the Placing and Subscription, are subject to the approval of shareholders of the Company at a General Meeting to be held at 11.00 a.m. on Tuesday, 30 June 2009.
It is expected that dealings in the 181,631,937 ordinary shares of 0.1p each issued pursuant to the Offer and the Placing and Subscription will commence on AIM on 1 July 2009.
Details of the Offer, the Placing and Subscription were set out in the announcement published by the Company on 12 June 2009.
For further information
Allergy Therapeutics |
+44 (0) 1903 845 820 |
Keith Carter, Chief Executive |
|
|
|
|
|
Nomura Code Securities |
+44 (0) 207 776 1200 |
Juliet Thompson/ Clare Terlouw |
|
|
|
Financial Dynamics |
+44 (0) 207 831 3113 |
Ben Brewerton/ Susan Quigley |
|